Additionally, administration of the CB2 antagonist—AM630—abolished the anti-glioma effect of JWH133 and abrogated the activation of ERK pathway and the increased expression of CYP2J2/11,12-EET after JWH133 treatment. Here, CYP2J2 is linked to central nervous system cancer.